기사
Prodizen completes PRP kit China CFDA registration
- 작성일 : 2023.06.28
- 조회수 : 123
[Raon Newspaper Reporter Park Eun-ah]
On the 28th, Prodizen subsidiary Medisarang (CEO Shim Soo-ja) reported the completion of PRP (self-platelet rich plasma treatment) kit Chinese CFDA registration.
Since 2008, Prodizen, a global biotechnology company, has launched and sold PRP Kit in Korea that has passed new medical technologies for epigastric inflammation, infertility, and dry eyes. In July 2021, it obtained the first US FDA 510k certification in Korea and was recognized for its quality worldwide. In addition, PRP kits are currently being exported to more than 30 countries through various patents and certifications.
▲ (사진=메디사랑 제공)
Prodizen subsidiary MediSarang signed an OEM agreement with an orthopedic company in China in August 2019 and began China FDA Grade II certification in 2020. Officials explain that China's FDA level 2 certification was completed in May this year, and it has already exported the first batch of $100,000 to China, and sales of around $1 million per year are expected from 2024.
A company official said, "The Chinese company that completed the contract this time has many clients in the Chinese orthopedic market, and we expect it to have a good synergy effect with Prodizen PRP. We will continue to work harder to show more convenient technologies," he said.
이전글
다음글